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Abstract: 
Background: Derivative based a-priori structural identifiability analyses of mathematical models can 
offer valuable insight into the identifiability of model parameters.  However, these analyses are only 
capable of a binary confirmation of the mathematical distinction of parameters and a positive 
outcome can begin to lose relevance when measurement error is introduced.  This article presents 
an integral based method that allows the observation of the identifiability of models with two-
parameters in the presence of assay error.   
Methods: The method measures the distinction of the integral formulations of the parameter 
coefficients at the proposed sampling times.  It can thus predict the susceptibility of the parameters 
to the effects of measurement error.  The method is tested in-silico with Monte Carlo analyses of a 
number of insulin sensitivity test applications.   
Results: The method successfully captured the analogous nature of identifiability observed in Monte 
Carlo analyses of a number of cases including protocol alterations, parameter changes and 
differences in participant behaviour.  However, due to the numerical nature of the analyses, 
prediction was not perfect in all cases.   
Conclusions: Thus although the current method has valuable and significant capabilities in terms of 
study or test protocol design, additional developments would further strengthen the predictive 
capability of the method.  Finally, the method captures the experimental reality that sampling error 
and timing can negate assumed parameter identifiability and that identifiability is a continuous 
rather than discrete phenomenon. 
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1.  Background 
A number of physiological phenomena have been modelled by formulating mathematical 
representations of the relevant interactions.  These models frequently incorporate variable 
parameters that can be identified to match the model representation to the observed behaviour.  
The value of these parameters is then used to characterise or quantify the response.  However, with 
complex or large models, variable parameters can be selected that seem mathematically distinct, 
but in reality define the same observable effect and identification failure is certain.  Thus, model 
identifiability analyses are used to test the selection of model parameters and ensure that they are 
mathematically distinct.   
Approaches for the analysis of model identifiability typically assume continuous perfect input data 
[1-3].  However, these derivative-based identifiability methods can produce false assurances of 
identifiability.  Recent dissatisfaction with the classical algorithms has resulted in the development 
of new methods that recognise assay error and discrete measurements as critical to identifiability [4, 
5].  The limitation of discrete data that is often subject of assay error often causes parameter trade-
off [6-9] and thus limitation of the identified metrics clinical value.  Thus, not only should a model be 
checked for identifiability in the classical a-priori sense, but the susceptibility of parameters to 
mutual interference should also be tested.   
For example, the Minimal Model of insulin sensitivity [10] has been shown to be identifiable using 
such methods [11-13].  However, with discrete data that is subject to assay error, parameter 
identification has sometimes failed [6, 7, 14].  Numerous Bayesian techniques have had success in 
limiting this failure [7, 15-17], but they tend to force the parameters to diverge away from their true 
least square values, limiting the relevance of the model and exaggerating the influence of population 
trends on an individual test’s identified parameter values.  Thus, widespread clinical application of 
these models has been limited by the ambiguity of results.  
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This article presents a novel graphical method for identifiability analysis that allows an identifiability 
analysis with consideration of noise and assay error.  Furthermore, the method highlights areas for 
potential improvements to protocols and sampling times that would improve practical identifiability.  
At this stage of development, the method is limited to first-order, two-parameter models that allow 
a separation of parameters, but are typical of those found in pharmacokinetic (PK) and 
pharmacodynamic (PD) modelling.   
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2.  Method and Study Design 
The proposed method will be evaluated in-silico using clinically validated models of insulin kinetics 
and the dynamic between insulin concentration and glucose decay.  The method’s ability to predict 
the variation behaviour of identified parameters in a Monte Carlo analysis will be tested.   
2.1 Proposed method process 
To evaluate identifiability of a model, the integral formulations of the parameters are evaluated 
using an estimated test stimulus response.  Thus, the method cannot be used in complete ignorance 
of the expected behaviour of the test participant.  In particular, the approximate shape of the 
species concentrations as a result of the test protocol must be estimated, (this is a reasonable 
assumption in most PK/PD studies).  The specific steps are illustrated using a generalised function: 
?̇? = 𝑓(𝑋,𝑌,𝐶,𝐷,𝑎, 𝑏) i 
where: X is a measured species with a discrete resolution, Y is a species that is co-dependent with X 
and is not measureable, C and D are independent known input profiles, and a and b are unknown 
model parameters 
1. Rearrange governing equation to create a first order differential equation with separated 
parameters in terms of a-priori, constant and measurable concentration terms 
?̇? = 𝑎𝑓1(𝑋,𝑌,𝐶) + 𝑏𝑓2(𝑋,𝑌,𝐶) + 𝐷 ii 
2. Derive the integral formulation of this governing equation 
𝑋𝑖 − 𝑋0 = 𝑎 ∫ 𝑓1(𝑋,𝑌,𝐶)𝑑𝑡𝑖0 + 𝑏 ∫ 𝑓2(𝑋,𝑌,𝐶)𝑑𝑡𝑖0 +∫ 𝐷𝑑𝑡𝑖0  iii 
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where: i is each measured sample time after the first. 
3. Evaluate the integral of the coefficients of each parameter between 0 and each proposed 
sample time using an assumed participant response to the test stimulus. 
𝑎� = � 𝑓1(𝑖
0
𝑋,𝑌,𝐶)                         𝑏� = � 𝑓2(𝑖
0
𝑋,𝑌,𝐶) iv 
4. Divide the resulting values by their respective means to normalise the coefficients.   
𝑎� = 𝑎�/𝑎��                                           𝑏� = 𝑏�/𝑏�� v 
5. Subtract one set of coefficients from the other and define the 2-norm of the result (‖∆‖2). 
‖∆‖2 = �𝑎� − 𝑏��2 vi 
6. Any distinction at all between the coefficients would imply identifiability (i.e.  if ‖∆‖2 ≠ 0).  
In reality, the effect of assay error on parameter identification is inversely proportional to 
the magnitude of this distinction (and proportional to the magnitude of any assay error (𝜀)):  
𝑉𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝜇 𝜀
‖∆‖2
 1 
where: 𝜇 is a proportionality factor that incorporates factors such as the relative 
contribution of the parameter to the derivative of the relevant species concentration in the 
governing differential equation, and the absolute magnitude of the noise at the sampled 
times in relation to the relative magnitude of the parameter coefficient. 
Thus, the method cannot accurately predict the coefficient of variation that a Monte Carlo analysis 
may find.  However, it can predict the change of variation that might be observed when changes are 
made to the test sampling or stimulus protocols. 
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2.2 The dynamic insulin sensitivity and secretion test (DISST) model 
2.2.1 Insulin pharmacokinetics 
Initially, a validated model of insulin PKs [18, 19] is used to evaluate the method described, and is 
defined: 
𝐼̇ = −𝑛𝑘𝐼 − 𝑛𝐿 𝐼1 + 𝛼𝐼𝐼 − 𝑛𝐼𝑉𝑃 (𝐼 − 𝑄) + 𝑥𝐿𝑈𝑁 + 𝑈𝑋𝑉𝑃  2 
?̇? = 𝑛𝐼
𝑉𝑄
(𝐼 − 𝑄) − 𝑛𝐶𝑄 3 
where: equation nomenclature is defined in Table 1 
Symbol definition units 
I Plasma insulin concentration mU/L 
Q Interstitial insulin concentration mU/L 
UN Endogenous insulin production rate profile mU/L/min 
UX Exogenous insulin bolus mmol 
nK Renal clearance of plasma insulin 1/min 
nL Hepatic clearance of plasma insulin 1/min 
nC Insulin clearance to cells 1/min 
nI Transition of insulin between plasma and interstitium L/min 
𝛼𝐼 Saturation of hepatic insulin clearance L/mU 
xL First pass clearance of insulin 1 
VP Distribution volume of plasma insulin L 
VQ Distribution volume of interstitial insulin L 
Table 1.  Nomenclature from Equations 2 and 3 
The model is used in the dynamic insulin sensitivity and secretion test (DISST) to define the PKs of 
insulin due to test stimulus [18, 20].  The model assumes that plasma insulin (I) is sampled.  A 
traditional derivative based identifiability analysis of the model presented in Equations 2 and 3 using 
Ritt’s pseudo-division algorithm [1, 21] is presented in Appendix 1. 
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2.2.2 Pharmaco-dynamics of glucose and insulin 
The parameters of the glucose-insulin PDs can also offer insight into the identifiability of parameters.  
The DISST model of glucose-insulin PDs is defined [18, 19]: 
?̇? = −𝑝𝐺(𝐺 − 𝐺𝑏) − 𝑆𝐼(𝐺𝑄 − 𝐺𝑏𝑄𝑏) + 𝑃𝑋𝑉𝐺 4 
where: equation nomenclature is defined in Table 2. 
Symbol definition units 
G Glucose concentration mmol/L 
Q Interstitial insulin concentration mU/L 
Gb Basal glucose concentration mmol/L 
Qb Basal interstitial insulin concentration mU/L 
pG Glucose dependant glucose clearance 1/min 
SI Insulin sensitivity L/mU/min 
PX Exogenous glucose bolus mmol 
VG Glucose distribution volume L 
Table 2.  Nomenclature from Equation 4 
Although the structural identifiability of Equation 4 is trivial it is also presented in Appendix 1. 
2.3 Participants 
Parameter values from two participants of the pilot investigation of the DISST [18] are used to 
generate in-silico simulated data to construct and demonstrate the method proposed here.  In-silico 
data is used in this analysis because it allows protocols to be changed to illustrate the impact on 
identifiability.  The participant characteristics are summarised in Table 3 and represents the 
extremities of the range of cases encountered in typical research studies of insulin sensitivity. 
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Glucose 
tolerance 
Sex Age BMI 
UN† I clearance 
VG SI 
Ub U1 U2 nL xL 
NGT M 22 21.5 26.6 487.7 9.7 0.218 0.797 9.75 20.95 
IGT* F 57 33.9 115.5 233.6 150.7 0.064 0.822 13.35 2.236 
Table 3.  Anatomical and identified parameter values (using the iterative integral 
method) of normal-glucose tolerant (NGT) and impaired glucose tolerant (IGT) 
participants of the DISST pilot investigation.  (* The IGT participant had suspected, yet 
un-diagnosed, type 2 diabetes at the time of testing, † Ub, U1 and U2 represent the 
basal, first and second phases of insulin production, respectively [mU/min]) 
2.4 Simulated test protocol 
The simulated protocol is similar to the DISST test; a 10g glucose bolus is administered at t=7.5 and a 
1U insulin bolus at t=17.5.  The test duration is 60 minutes with a 5 minute sampling frequency.  The 
UN profile is defined as a step function with three stages including basal, first and second phase 
production rates.  The first phase of insulin production has a five-minute duration and begins with 
the glucose bolus.  Simulations of plasma and interstitial insulin are completed using Equations 2 and 
3, the parameter estimation equations from [22], nL and xL values from Table 3 and an aI value of 
0.001L/mU.  Glucose is simulated using Equation 4 and the interstitial insulin profile obtained in the 
evaluation of Equations 2 and 3. 
2.5 Iterative integral method 
The analyses of this study will use the iterative integral method to identify parameters [20, 23].  
Although the method has been presented [20], it is repeated in brief in Steps 1-5 below:  
1. The method converts the model governing equations to their integral formulation.   
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2. The parameter coefficients and the remainder terms are evaluated between t=0 and the 
sample times. 
3. The coefficients form the LHS of a matrix equation in terms of the parameters, while the 
remainder terms form the RHS.  This matrix is evaluated to get parameter values. 
4. These parameter values are used to update the coefficient evaluations in step 2, which 
enables a more accurate matrix equation in step 3. 
5. Step 4 is iterated until convergence is achieved. 
2.6 Analysis 
A series of parameter and sampling scenarios were analysed using the models presented in a Monte 
Carlo analysis.  Clinically measured physiological parameters of the NGT participant presented in 
Table 3 were used to define simulated responses to the test protocol described in Section 2.4.  
Samples were obtained from the simulated profiles at the defined times.  Each iteration of the 
Monte Carlo analysis adds normally distributed assay error (the error magnitude is defined within 
each section).  100 iterations are used for each analysis with parameter identification by the iterative 
integral method.  Only simulated profiles from the NGT participant are used until Section 3.2.2.  Each 
scenario will present the mean value of those identified in the Monte Carlo simulation normalised by 
the simulation value from Table 3, and the coefficient of variation (CV) of each identified parameter 
(i.e.  A mean of 1 and standard deviation of 0 implies perfect identification).  The CV values are the 
paramount indicator of parameter trade-off during identification.  The CV values are thus was 
compared to the 𝜀/‖∆‖2  value defined using the methods of Section 2.1 to obtained values for 𝜇 
that linearise Equation 1. 
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2.7 Cases tested 
A series of indicative cases will be investigated to show how the selection of model parameters, 
sample placement, participant behaviour and protocol dosing can have an effect on model 
identifiability. 
• The insulin pharmacodynamic model will include five variable parameters to be identified 
to confirm the robustness and convexity of the iterative integral method, and to confirm 
the findings of the traditional derivative-based identifiability analysis. 
• Parameter interference of nL and nK will be analysed.  The nature of identifiability will be 
explored by alteration of the 𝛼𝐼 term that moderates the denominator of nL in Equation 
2.  
• The effect of sample selection on parameter identification of nT and VP will be measured.  
(nT is the addition of nL and nK). 
• The effects of sample omissions on SI and VG identification are measured. 
• The disparity of parameter identifiability in insulin resistant and sensitive individuals will 
be assessed using pG and SI as variable model parameters 
• The protocol proposed in Section 2.4 will be altered to see if the identifiability of insulin 
resistant participants can be improved. 
• Measured samples that the proposed method claims are not valuable to stable 
identification are ignored and the identification process is repeated to confirm the 
prediction. 
All cases will be tested with 1% and 3.5% normally distributed noise added to the virtually obtained 
data (to a maximum of 3 standard deviations).  
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3.  Results 
3.1 Analysis of the insulin pharmacokinetic model 
3.1.1 Confirmation of global model identifiability 
When the sampled data is used in the iterative integral method to define nL, nK, nI/VP, xL and VP as 
parameters, convergence to the simulation values occurs (Figure 1).  This confirms the traditional 
identifiability analysis of Equations 2 and 3 in Appendix 1.  However, when 1% normally distributed 
noise is added to the simulated data, parameter values do not converge to simulation values (Figure 
1).  When the sample noise is increased to 3.5%, which is more indicative of actual measurement 
noise encountered clinically, parameter convergence is significantly biased.  Hence despite proven 
(no noise) structural identifiability, the addition of assay error or noise yields corrupted or 
potentially unidentifiable results. 
3.1.2 Hepatic and renal clearance rate identification  
To understand why the addition of noise disables the identification, the case of interference 
between nK and nL is tested.  In this analysis, all parameters of Equations 2 and 3 are set as constants 
and only nL and nK are identified as parameters.  From the analyses in Appendix 1 and Section 3.1.1, 
parameter convergence is assured for the noiseless case.  However, for the 1% and 3.5% noise cases 
parameter interference causes considerable parameter divergence in the value of the identified 
parameters compared to the actual values used in-silico.  The Monte Carlo analysis described in 
Section 2.6 is used to evaluate these parameters in the presence of noise and the results are shown 
in Table 4.   
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The matrix equation used by the iterative integral method is a re-arrangement of Equation 2 and is 
in the form: 
−𝑛𝑘 � 𝐼𝑑𝑡
𝑖
0
− 𝑛𝐿 �
𝐼1 + 𝛼𝐼𝐼 𝑑𝑡𝑖0
= 𝐼𝑖 − 𝐼0 + 𝑛𝐼𝑉𝑝� (𝐼 − 𝑄)𝑑𝑡𝑖0 − 𝑥𝐿 � 𝑈𝑁𝑑𝑡𝑖0 + � 𝑈𝑋𝑉𝑝𝑑𝑡𝑖0  2a 
where: i= 5, 10, 15, … ,60 minutes, matching sampling times. 
Thus, the value of the ‖∆‖2 term can be obtained for this model and sampling protocol as: 
‖∆‖2 = �� ∫ 𝐼𝑑𝑡𝑖01
𝑛∑∫ 𝐼𝑑𝑡
𝑖
0
� − �
∫
𝐼1 + 𝛼𝐼𝐼 𝑑𝑡𝑖01
𝑛∑∫
𝐼1 + 𝛼𝐼𝐼 𝑑𝑡𝑖0 ��2 = 0.03187  
However, Table 4 shows that if aI is increased significantly to 0.05 L/mU, an arbitrarily chosen value 
that is not necessarily representative of physiology [24], parameter convergence is more stable.  The 
‖∆‖2 term can be re-identified with the exaggerated 𝛼𝐼 value.   
‖∆‖2 = �� ∫ 𝐼𝑖0 𝑑𝑡1
𝑛∑∫ 𝐼𝑑𝑡
𝑖
0
� − �
∫
𝐼1 + 𝛼𝐼𝐼𝑖0 𝑑𝑡1
𝑛∑∫
𝐼1 + 𝛼𝐼𝐼 𝑑𝑡𝑖0 ��2 = 0.46377  
Thus, the parameters identified with the exaggerated 𝛼𝐼 term should have approximately 15 times 
smaller variability than those identified with the accepted 𝛼𝐼 value.  Table 4 shows the effect of the 
𝛼𝐼 distinction on the identified parameter values. 
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Noise 0% 1% 3.5% 
Saturation 𝜶𝑰=0.001 𝜶𝑰=0.05 𝜶𝑰=0.001 𝜶𝑰=0.05 𝜶𝑰=0.001 𝜶𝑰=0.05 
nK 1(0) 1(0) 0.952(0.297) 0.999(0.017) 0.946(0.836) 1.004(0.059) 
nL 1(0) 1(0) 1.035(0.214) 1.001(0.008) 1.041(0.595) 1.000(0.028) 
Table 4.  The normalised parameter variation (mean(CV)) when nK and nL are identified 
parameters with distinct simulated assay error and values for 𝛼𝐼.  (1(0) indicates perfect 
convergence to the simulation value) 
Table 4 shows the distinction between the effects of noise on identified parameters when the 𝛼𝐼 
term is changed.  Although the 0% noise case indicates that the parameters are uniquely identifiable, 
at 1% noise the variation in the identified values limits their clinical viability.  At 3.5% noise, which 
may be expected in a real clinical setting, the parameters are no longer uniquely identifiable.  This is 
illustrated by the very large CVs of the parameters.  However, when the 𝛼𝐼 term is significantly 
increased, unique identifiability is once again possible, even with 3.5% noise.  The mean ratio of 
variation caused by the disparate aI values was approximately 1:20.  This is larger than the ratio 
predicted by the method (1:15), but still represents a positive outcome in terms of predicting the 
relative magnitude of the change. 
The reason for this outcome can be observed in the increased contrast between integral 
formulations of the parameter coefficients.  The contrast is shown graphically in Figure 2. 
The difference between the curves at the sample times indicates the identifiability of the model 
parameters in this two-parameter case.  Thus, when the saturation term is increased, the 
coefficients of the parameters are more distinct and identifiability is increased.  Despite the positive 
findings of the typical identifiability analysis, a saturation value of 0.001L/mU causes nK and nL to 
become uniquely un-identifiable in a real clinical setting.  This outcome may be considered as an 
elementary finding that should be inferred with a quick observation of Equation 2.  However, it 
points to a failing of typical a-priori identifiability tests that this approach can negate with a quick 
graphical analysis.   
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The findings of this analysis also show that the functional effects of nL and nK on insulin 
concentration in Equation 2 are so similar that there would be a negligible effect if the terms are 
combined.  As such, further analysis of this model will use a combined nL and nK term (nT) without 
the saturation term, which is negligible except at extremely high insulin concentrations.  Equation 2 
is thus redefined in Equation 5: 
𝐼̇ = −𝑛𝑇𝐼 − 𝑛𝐼𝑉𝑃 (𝐼 − 𝑄) + 𝑥𝐿𝑈𝑁 + 𝑈𝑋𝑉𝑃  5 
3.1.3 Plasma insulin distribution volume and insulin clearance identifiability 
To identify nT and Vp the form of the governing matrix equation is: 
𝑉𝑃���� (𝑛𝐼(𝑄 − 𝐼) + 𝑈𝑋)𝑑𝑡𝑖
0
− 𝑛𝑇 � 𝐼𝑑𝑡
𝑖
0
= 𝐼𝑖 − 𝐼0 − 𝑥𝐿 � 𝑈𝑁𝑑𝑡𝑖
0
 5a 
where: 𝑉𝑃���=1/VP 
As with the nK and nL analysis, the 0% noise case exactly reproduced the simulation values.  Figure 3 
shows the coefficients of the two parameters and three sampling protocols.  In this case, Protocol 1 
uses the 5 minutely sampling defined in Section 2.4.  However, Protocol 2 uses samples at t=0, 15, 
20, and 60, and Protocol 3 uses samples at t=0, 5, 45, and 60 minutes.  Thus, Protocol 1 requires 13 
samples while both protocol 2 and 3 only require four samples. 
The ‖∆‖2 terms can be defined for each of these protocols (Table 5) and the coefficients are 
displayed graphically in Figure 3. 
 ‖∆‖𝟐 
Protocol 1 0.73067 
Protocol 2 0.99013 
Protocol 3 0.044607 
Table 5.  The value of the ‖∆‖2 term for the three sampling protocols defined. 
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The ‖∆‖2 values indicate that Protocol 3 will be comparatively unable to reproduce the simulation 
values.  Contrary to the expected result that parameter identification is best with frequently 
sampled Protocol 1, the method predicts that the sparsely sampled Protocol 2 will be slightly more 
accurate. 
Table 6 shows the parameter convergence and variability for the exact same model with the three 
different sampling protocols. 
Noise 1% 3.5% 
Protocol 1 2 3 1 2 3 
nT 1(0.004) 1(0.003) 0.973(0.012) 1.003(0.012) 1.001(0.014) 0.958(0.045) 
VP 1.001(0.014) 0.995(0.012) 1.231(0.175) 0.999(0.047) 0.995(0.051) 1.190(0.463) 
Table 6.  The effect of the sampling protocols on the identifiability of nT and VP as 
defined by the normalised mean and (CV) of the identified values. 
It is evident that although Protocols 2 and 3 contain the same number of samples, the resolution of 
the identified parameters is considerably reduced in Protocol 3.  In effect, 𝑉𝑃���� was un-identifiable 
with Protocol 3.  This result occurs because of the lack of distinction in the coefficients of the 
parameters at the sample times as indicated in Table 5 and Figure 3.   
Thus, the method predicted the poor performance of the third protocol while it predicted much 
lower variability for both Protocols 1 and 2.  However, it also suggests that Protocol 2 would improve 
slightly upon Protocol 1, which was not the case as both protocols performed equally in terms of 
parameter identifiability.  It is expected that it’s equality of variance is an artefact of the 
normalisation as a function of mean coefficient at the sample value, artificially lowering the 
magnitude of the ‖∆‖2 terms in Protocol 1. 
Overall, these findings highlight the inefficiency, extreme clinical burden and intensity of frequent 
sampling in contrast to well-positioned and infrequent sample timing.  More specifically, Protocol 1 
used 9 more samples than Protocol 2 with significant added clinical intensity and assay cost (~200% 
more!) for absolutely no information gain.  This outcome was successfully predicted by the 
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identifiability analysis method presented. 
3.2 Analysis of the glucose PD model 
Equation 4 will be used in the analysis of identifiability of terms frequently used to model the PDs of 
insulin and glucose.  All analyses in this section will simulate insulin concentration profiles for the 
plasma and interstitium only once for each Monte Carlo analysis.  Thus for clarity and simplicity, it is 
assumed that insulin is not subject to assay error here.  Furthermore, while glucose assay error from 
a blood gas analyser is approximately 2%, errors of 1% and 3.5% will be used for consistency with 
Section 3.1.  As such, the resultant coefficients of variation should not be considered fully applicable 
clinically, but merely as an indication of parameter trade-off during identification.  The Monte Carlo 
analysis method with the NGT participant described in Section 2.3 is repeated for the glucose PD 
model.  The IGT participant will be used in tandem with the NGT participant from Section 3.2.2. 
3.2.1 Insulin sensitivity and distribution volume 
Use of the DISST model typically entails the identification of SI and VG in Equation 4 [18, 20, 25].  As 
such, this case is tested using the proposed method and three potential sampling protocols.  
Specifically, Protocol 1 uses the 5-minute sampling resolution described in Section 2.4, while 
Protocols 2 and 3 use 10 and 20-minute resolutions, respectively.  Figure 4 and Table 7 indicate that 
these parameters are uniquely identifiable in the presence of measurement noise given a 
surprisingly small number of data points. 
 1% 3.5% 
Protocol 1 2 3 1 2 3 
SI 1.001(0.007) 1.002(0.008) 1(0.016) 1.002(0.028) 1.002(0.033) 1.010(0.054) 
VG 1(0.012) 1(0.014) 1.001(0.029) 0.998(0.046) 1.001(0.049) 0.990(0.087) 
Table 7.  The normalised mean and (CV) of the glucose PD parameter values from the 
three proposed sampling resolutions. 
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Table 7 shows that parameter stability is generally very high even in a sparsely sampled data set with 
a relatively high level of noise.  This result was expected due to the relatively large difference in the 
coefficient integrals shown in Figure 4 for each of the sampling protocols.  Thus, like the case of VP 
and nT, intelligent sample timing can significantly reduce clinical burden and study cost with 
negligible loss of information.  Furthermore, the proposed method successfully predicted this 
outcome. 
3.2.2 Insulin sensitivity and glucose dependent decay 
Model-based studies of insulin sensitivity frequently identify a parameter synonymous with pG in 
addition to SI and VG as parameters when using the Minimal Model [10] or similar.  However, 
although these parameters are mathematically distinct, they are known to trade-off during 
identification and practical identifiability is not generally assured.  It has been reported that these 
issues can be exacerbated for insulin resistant (IR) individuals [7, 8].  Thus, the second, IGT 
participant defined in Table 3 will also be analysed. 
Some insight into the parameter trade-off during identification of dynamic test data can be seen in 
Figure 5 that contrasts the integral formulations of the parameter coefficients based on glucose 
tolerance status.  The contrasting shape of the integral formulations of the parameter coefficients is 
best observed in the pG coefficient.  The pG coefficient is the only term in Equation 4 that could 
possibly become negative.  Thus, the integral of the coefficient can form a convex shape that 
contrasts well with the coefficient of SI as seen for the NGT participant in Figure 5.  However, the 
negative coefficient of pG can only occur when the participant’s glucose concentration goes below 
the basal concentration.  Thus, as only NGT participants achieve such concentration reductions in 
typical dynamic insulin sensitivity tests, the parameter identifiability of IR participant is impaired in 
comparison.  In particular, Figure 5(right) shows minimal difference and a much smaller ‖∆‖2 value 
for this IR individual indicating increasing potential for parameter trade-off in the identification 
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process and loss of effective identifiability.  This is despite an identical test protocol and model. 
As mentioned, this limitation of the Minimal Model has been reported, but not explained in the 
literature until now. 
Table 8 shows the parameter error when the 60 minute 10-minute sampling protocol is used. 
Noise 1% 3.5% 
Participant NGT IR NGT IR 
SI 1(0.008) 1.001(0.161) 0.998(0.032) 0.876(0.449) 
pG 1.009(0.320) 0.959(0.756) 1.109(0.802) 1.573(1.244) 
Table 8.  Normalised mean and (CV) values of the identified parameters contrasting the 
identifiability of parameters based on the participant test response. 
It is apparent that the insulin resistant individual’s parameter identifiability is much lower than the 
NGT participant despite the identical PD model, test protocol and identification process.  Table 8 
highlights this result, as well as the increasing loss of identifiability as assay error increases.  This is in 
accordance to published findings and the proposed method’s prediction.   
3.2.3 A hypothetical protocol to enable pG identification in dynamic tests 
To forcibly remove this ambiguity introduced by the comparable coefficients of the IR individual, the 
protocol of the DISST could be altered.  After an initial observation of the effect of the insulin bolus 
on glucose concentration, more insulin could be introduced to ensure that the participant’s glucose 
concentration is maintained approximately 0.5mmol/L below the basal concentration.  Such a 
protocol may include an extension of the protocol described in Section 2.4 wherein a period of slight 
hypoglycaemia is achieved for each participant with a series of participant-specific insulin boluses 
administered with feed-back control. 
To allow a fair comparison between the variability of the parameters of the proposed protocol and 
the protocol used in Section 3.2.2 the sampling regimen and test duration will be maintained.  Thus, 
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the additional insulin is administered as a bolus t=32.5 minutes.  In a clinical setting, the magnitude 
of the bolus would be participant-specific and dependent on the glucose concentration response 
alone (as glucose can be assayed in real-time).  Note that this task would be very difficult and 
potentially dangerous in a regular clinical setting.  In particular, the amount of insulin required would 
vary between participants, and must be estimated in ignorance of endogenous insulin production.  
This may cause a high incidence of potentially harmful hypoglycaemia.  This protocol is only mooted 
to illustrate the ability of the method, and in reality the introduction of additional insulin could be 
applied slowly and safety would be assured. 
For the case of the IR participant presented here, reducing glucose sufficiently would require a 3U 
bolus at t=32.5 minutes.   
The proposed protocol would alter the shapes of the integral of the parameter coefficients for the 
resistant individual.  In doing so, it is hypothesised that it would increase the distinction between 
these curves to avoid the similarity seen in Figure 5(right) to ensure identifiability.  The ‖∆‖2 value 
obtained for the IGT participant and the updated protocol indicates a reduction in variability ratio of 
approximately 1:2.2.  Figure 6 contrasts with Figure 5(right) as it shows how the added bolus 
significantly increases the distinction between the coefficients of the identified parameters.  Table 9 
shows the outcomes of this analysis. 
Noise 1% 3.5% 
SI 1.002(0.029) 0.996(0.070) 
ΔSI +0.001(-0.132) +0.120(-0.379) 
pG 0.989(0.369) 0.992(0.969) 
ΔpG +0.030(-0.387) -0.581(-0.275) 
Table 9.  Parameter convergence from the proposed hypothetical protocol.  ΔSI and ΔpG 
show the change between these values and those from the same individual presented 
in Section 3.2.2.  The bold ΔCV values are the critical finding of this analysis. 
Although the inhibitive CV values for the parameters indicate that the proposed protocol could not 
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be used clinically, the variability decreased in the order predicted by the identifiability method 
presented.  The hypothetical protocol presented has confirmed the reasons discussed for the poor 
parameter identification observed in many clinical studies which utilise these two competing 
parameters [7, 8].  Furthermore, it demonstrates a limitation of traditional identifiability methods, 
which provide an evaluation of identifiability in ignorance of probable participant behaviour or test 
protocol design.   
The protocol presented would be virtually impossible to apply clinically in the 60 minute duration as 
it is shown here.  However, this analysis was limited by the need for a comparable duration and 
sampling regimen to Section 3.2.2.  The method could thus be used to define similar protocols that 
could yield data that enables unique identification of these parameters.  If such protocols are 
pursued, they would most likely require two sections in a much longer test.  The first section would 
involve the protocol defined in Section 2.4, and would be followed immediately by an infusion of 
insulin designed to safely bring the participant’s glucose concentration to 0.5 mmol/L below the 
basal level.  Robust results would be most assured if the participant’s glucose concentration was 
maintained below this level for approximately 30 minutes, and thus, the protocol would most likely 
require about 2 hours.  However, a stable result both in terms of SI and pG would be generally 
assured. 
3.2.4 Removal of redundant points 
The t=40 minute sample in Figure 5(left) and t=30 in Figure 5(right) show virtually no distinction 
between the coefficients of either profile.  Thus, according to the theory presented, it should 
provide no value to the identification process.  To test this, the analysis of Section 3.2.2 is repeated 
with these samples removed.  Figure 7 shows how the omitted data point do not significantly alter 
the distinction shown in Figure 5 (Section 3.2.2).  Table 10 shows how the identified parameters 
were affected by the omission of data that the method implied were redundant. 
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Noise 1% 3.5% 
Participant NGT IR NGT IR 
SI 0.999(0.010) 0.960(0.182) 1(0.029) 0.852(0.496) 
ΔSI -0.001(+0.002) -0.041(+0.021) +0.002(-0.003) -0.024(+0.047) 
pG 1.019(0.360) 1.152(0.693) 1.400(0.762) 1.231(1.156) 
ΔpG +0.010(+0.040) +0.193(-0.063) +0.311(-0.040) +0.342(-0.088) 
Table 10.  Parameter normalised mean and (CV) values of identified parameters with 
the omission of the assumed negligible data points.  ΔSI and ΔpG are the change in 
values between this analysis and Section 3.2.2.  The bold ΔCV values are the key finding 
of this analysis. 
The findings of this analysis imply that the omission of the samples that were assumed to be 
obsolete had little effect on the outcome of the identification process.  Most changes were very 
small and only those for the particularly un-stable parameters showed any significant changes.   
3.3 The value of μ 
The value of μ in Equation 1 can be used to enable prediction of the probable variability in the 
identified parameters in a Monte Carlo simulation.  Thus, the effects of protocol changes on the 
parameter identifiability can be predicted without the need for numerous Monte Carlo simulations.  
To identify the value of μ linear relationships between the CV values obtained and the 𝜀/‖∆‖2 values 
are defined.  As noiseless identifiability of all models has been proven, the y-intercept can be 
assumed at zero, and μ can be identified using Equation 6: 
𝜇 = 1
𝑁
�
𝐶𝑉(𝜀/‖∆‖2) 6 
Figure 8 shows the adherence of μ to linear relationships while Table 11 shows the value of μ for the 
different parameters.   
 Table 11 presents the μ values identified by the gradients of the regression lines 
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Analysis Parameter μ 
Section 3.1.2 
nL 0.560 
nK 0.801 
Section 3.1.3 
nT 0.081 
VP 0.683 
Section 3.2.1 
SI 1.48 
VG 2.41 
Sections 3.2.2 
and 3.2.4 
SI 6.45 
pG 26.0 
Table 11.  Values for μ from the various analyses 
It can be observed that no single value for μ can be applied across all models and that different 
parameters are considerably more susceptible to the distinction of the parameter coefficients.  
However, the general adherence to the linear relationships observed in most examples implies that 
the form of Equation 1 is accurate for this purpose with the possible exception of SI in Sections 3.2.2 
and 3.2.4.   
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4.  Conclusions 
The method presented was able to predict and explain the parameter identifiability behaviour 
exhibited in models of insulin kinetics and insulin/glucose dynamics.  This capability is in direct 
contrast to the traditional derivative-based identifiability analysis [1, 3, 11-13] that can only provide 
a confirmation of an infinitesimal distinction of the parameters in the governing equations.  In 
addition to the ability to predict parameter identifiability, the method has been shown to be able to 
aid sample selection and explain the non-identifiability of the pG term in common insulin sensitivity 
tests for IR participants of dynamic tests.  It was also used to derive and justify a novel protocol to 
make this parameter more identifiable in this subgroup.  Furthermore, the method also accurately 
predicted sample redundancy. 
Like the proposed method, the method proposed by Raue et al. [4] recognises the ability of 
apparently identifiable parameters to become practically  non-identifiable in the presence of assay 
error and discrete sampling.  The Raue et al. method requires numerous simulations and parameter 
identification processes to characterise the model sensitivity to variations in each model parameter.  
In contrast, the proposed method allows a quick graphical analysis, which can produce immediately 
apparent and intuitive results.  Furthermore, the proposed method can quickly appraise protocol 
variants, and provide indications of the reason for practical non-identifiability.  The method of Raue 
et al. is a more general method as it can appraise most model configurations, whereas the proposed 
method is currently limited to models with two separable parameters.   
In reality, many models utilise more than two parameters to describe physiological kinetics and seek 
to identify all at once.  It is expected that development of the proposed method will enable 
identifiability analyses of such models.  However, more care must be taken to construct the 
coefficient integral formulations as combinations of parameters that may come into conflict.  This 
task would require the contrast between the most deleterious combinations of integral coefficients 
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to be measured.  However, this point was not explored in this study, as the goal was to introduce the 
overall approach. 
Only cases with separable parameters in terms of measured species were analysed.  In reality, some 
model parameters are intrinsically linked and this method will not work.  An example of linked 
parameters would be insulin sensitivity and insulin effect saturation that requires a Michaelis-
Menten formulation.  In addition, some parameters effect remote, un-measured concentrations or 
masses and are thus not able to be identified with this method.  For example, the nC term in 
Equation 3 could not be evaluated for identifiability using this method without the inclusion of 
measurements of interstitial insulin [26].  As such, this method should not replace the traditional 
identifiability analysis, but be used in tandem with it (or methods such as Raue et al. [4] or similar) to 
produce both theoretical and practical investigations of identifiability.   
Furthermore, the model assumes that an expected range of parameter values is known prior to the 
commencement of the clinical study.  This knowledge is important, as the method requires that 
species simulations are available to define the coefficients of the parameters.  However, in most 
cases, the researcher will be able to obtain an indication of the likely range of parameter values in a 
cohort from a brief literature search, and likely test outcomes could be cases that can be safely 
evaluated prior to clinical testing. 
There is also an assumption that the model captures all of the dynamics of the system perfectly.  In 
reality no model can provide such accuracy.  In particular, Figures 4-7 show a sample taken at t=10 
for glucose.  In reality, this sample will be affected heavily by error caused by incomplete mixing, and 
although the method presented indicates that this is a valuable sample, if it is used in the glucose 
pharmacodynamic model of Equation 5, the resultant parameters will be overly influenced by an un-
modelled mixing effect. 
Although the method has limitations and potential for improvement, it can provide valuable 
information at a study design stage, as well as valuable identifiability information not available from 
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typical methods.  It can differentiate between the applicability of different dynamic tests based on 
cohorts, and also help to define optimal sample timing and frequency.  In particular, it explained the 
observation of poor parameter convergence in the Minimal Model for insulin resistant participants 
that has been widely reported but without clearly defining the cause.  Thus, despite the method’s 
limitations, it should still be used in the design stage of a study to ensure that the resultant clinical 
data can provide usable results, and time and money is not wasted.   
Finally, the method has highlighted the limitation of discrete binary identifiability analyses as 
providing potentially misleading assurances of parameter identifiability in real clinical applications, 
and shown that identifiability is instead a continuous artefact of sample timing and the distinction 
between parameter coefficients. 
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Figure legends 
Figure 1.  Convergence of 5 parameter case 
Mean absolute percentage error between the simulation and identified parameters in the presence 
of 0%, 1% and 3.5% random assay error, with respect to iterations of the iterative integral 
identification approach. 
 
Figure 2.  Renal and hepatic clearance coefficient integrals 
The distinctions between the integral form of the hepatic and renal clearance coefficients when the 
standard (left) and exaggerated (right) 𝛼𝐼 values are used. 
 
Figure 3.  Plasma distribution volume and inuslin clearance coefficient integrals 
Parameter coefficient distinctions using the three similar clinical protocols with distinct sampling 
regimens. 
 
Figure 4.  Insulin sensitivity and glucose distribution volume coefficient integrals 
Distinction between the integral of the coefficients of the parameters of Equation 5 when differing 
sampling resolutions are used. 
 
Figure 5.  Insulin sensitivity and glucose dependent uptake in NGT and IR individuals 
The disparity between normo-glucose tolerant and insulin resistant individuals in terms of the 
distinction of the integral formulations of the coefficients of SI and pG. 
 
Figure 6.  Effect of an alternative protocol to maximise parameter distinction in IR individuals 
The effect of the added insulin bolus on the distinction of the coefficient integrals of pG and SI for the 
IR participant. 
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Figure 7.  Effect of omitting assumed negligible samples 
The coefficient comparison in alternative sampling protocols that omit the samples that according to 
Figure 5 have almost negligible value in terms of identifiability due to the very small magnitude of 
distinction at the sample times. 
 
Figure 8.  Linear regression of μ 
Comparisons between CV values and 𝜀/‖∆‖2 terms to provide parameter specific values for μ. 
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Appendix 1: Structural identifiability  
A1.1 Structural identifiability of the insulin model 
Using the method of algebraic derivative approach of [21] and refined in [1] the identifiability of the 
model can be confirmed.  Using the ranking:  
[𝑈𝑁 < 𝑈𝑋 < 𝑈?̇? < 𝑈?̇? < 𝑌 < ?̇? < ?̈? < 𝐼 < 𝑄 < 𝐼̇ < ?̇?] 
generates the characteristic set of Equations 2 and 3. 
−
𝑛𝐼
2
𝑉𝑃𝑉𝑄
𝑌 + �𝑛𝐶 + 𝑛𝐼𝑉𝑄� �?̇? + 𝑛𝐾𝑌 + 𝑛𝐿 𝑌1 + 𝛼𝑌 + 𝑛𝐼𝑉𝑃 𝑌 + 𝑈𝑋𝑉𝑃 + 𝑥𝐿(𝑈𝑁)�… 
               … + ?̈? + 𝑛𝐾?̇? + 𝑛𝐿 ?̇?1+𝛼?̇? + 𝑛𝐼𝑉𝑃 ?̇? + 𝑈?̇?𝑉𝑃 + 𝑥𝐿(𝑈?̇?) 
3a 
?̇? + 𝑛𝐾𝑌 + 𝑛𝐿 𝑌1 + 𝛼𝑌 + 𝑛𝐼𝑉𝑃 (𝑌 − 𝑄) + 𝑈𝑋𝑉𝑃 + 𝑥𝐿(𝑈𝑁) 2a 
if: 𝑌 = 𝐼  
Thus, the following coefficients can be defined: 
?̇?: (𝑛𝐶 + 𝑛𝐾 + 𝑛𝐼𝑉𝑃 + 𝑛𝐼𝑉𝑄) 𝑌: �𝑛𝐾 + 𝑛𝐼𝑉𝑃��𝑛𝐶 + 𝑛𝐼𝑉𝑄� − 𝑛𝐼2𝑉𝑃𝑉𝑄 
𝑌1 + 𝛼?̇?̇ :𝑛𝐿 𝑌1 + 𝛼𝑌 :𝑛𝐿(𝑛𝐶 + 𝑛𝐼𝑉𝑄) 
𝑈?̇?: 1𝑉𝑃 𝑈𝑋: 1𝑉𝑃 (𝑛𝐶 + 𝑛𝐼𝑉𝑄) 
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𝑈?̇?: 𝑥𝐿 𝑈𝑁: 𝑥𝐿(𝑛𝐶 + 𝑛𝐼𝑉𝑄) 
Using arbitrary values for the coefficients confirms global identifiability of the insulin kinetic model 
of Equations 2 and 3. 
A1.2 Structural identifiability of the glucose model 
The structural identifiability of the glucose model is considerably less complex than the insulin 
kinetic model.  In particular, the characteristic set is defined: 
 ?̇? + 𝑝𝐺(𝐺 − 𝐺𝑏) + 𝑆𝐼(𝐺𝑄 − 𝐺𝑏𝑄𝑏) − 𝑃𝑋𝑉𝐺 4a 
and thus the coefficients are defined: 
𝐺: 𝑝𝐺 𝐺𝑄: 𝑆𝐼 
𝑃𝑋: 1/𝑉𝐺 𝑄𝑏:𝐺𝑏𝑆𝐼 
and observation confirms that pG, SI, Gb and VG are globally identifiable using derivative-based 
identifiability analysis. 
